| Literature DB >> 29098086 |
Younsun Son1, Kyungun Kim2, Soeun Jeon3, Minsoo Kang4, Sukho Lee3, Yoonjung Park1.
Abstract
The objective of this meta-analysis is to summarize the effect of exercise intervention on flow-mediated dilatation (FMD) in overweight and obese adults. We searched four electronic databases (PubMed/Medline, Scopus, and CINAHL) through June 2016 for relevant studies pertaining to the effectiveness of exercise intervention on FMD. Seventeen of the 91 studies identified met the inclusion criteria. Comprehensive Meta-Analysis software (version 3) was used to compute the standardized mean difference effect size (ES) and 95% CI using a random effects model. We calculated 34 ESs. We found that exercise intervention had medium and positive effects on FMD, with an overall ES of 0.522 (95% CI = 0.257, 0.786). Heterogeneity of ESs was observed (Qb = 239, p ≤ 0.001, I2 = 86.19), and the effect was moderated by comorbidity (Qb = 6.39, df = 1, p = 0.011). A large ES for the combination exercise, low intensity exercise, and comorbidity subgroups (ES = 0.82~1.24) was found. We conclude that while exercise intervention significantly improves FMD in overweight and obese adults, the effect may depend on the different characteristics of exercise intervention and on participants' demographics.Entities:
Year: 2017 PMID: 29098086 PMCID: PMC5643022 DOI: 10.1155/2017/7532702
Source DB: PubMed Journal: Int J Vasc Med ISSN: 2090-2824
Figure 1Flowchart for selection of studies.
Baseline characteristics of the included studies.
| Author and year | County | Subject characteristics of treatment group | Subject characteristics of control group | Smoker | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample size | Gender | Age | Health status | BMI | Δ weight | Sample size | Gender | Age | Health status | BMI | Δ weight | |||
| Ades et al. (2011) a [ | USA | 23 | Both | 66 | Coronary heart disease | 32 | −8 | Not included | ||||||
| Ades et al. (2011) b [ | USA | 15 | Both | 62 | Coronary heart disease | 33 | −2 | Not included | ||||||
| Baynard et al. (2009) a [ | USA | 10 | Both | 52 | Metabolic syndrome | 34 | 0 | Not included | ||||||
| Baynard et al. (2009) b [ | USA | 10 | Both | 52 | Metabolic syndrome | 34 | 0 | Not included | ||||||
| Baynard et al. (2009) c [ | USA | 11 | Both | 53 | Healthy | 33 | 0 | Not included | ||||||
| Baynard et al. (2009) d [ | USA | 11 | Both | 53 | Healthy | 33 | 0 | Not included | ||||||
| Bhutani et al. (2013) a [ | USA | 18 | Both | 45 | Healthy | 35 | −6 | 25 | Both | 42 | Healthy | 35 | −3 | Not included |
| Bhutani et al. (2013) b [ | USA | 24 | Both | 42 | Healthy | 35 | −1 | 16 | Both | 49 | Healthy | 35 | 0 | Not included |
| Blumenthal et al. (2010) [ | USA | 49 | Both | 52 | HTN | 34 | −9 | 46 | Both | 52 | HTN | 33 | 0 | Included |
| Choo et al. (2014) a [ | South of Korea | 39 | Female | 42 | Healthy | 29 | −2 | Included | ||||||
| Choo et al. (2014) b [ | South of Korea | 39 | Female | 42 | Healthy | 29 | −2 | Included | ||||||
| Choo et al. (2014) c [ | South of Korea | 39 | Female | 42 | Healthy | 29 | −2 | Included | ||||||
| Choo et al. (2014) d [ | South of Korea | 26 | Female | 46 | Healthy | 28 | −2 | Included | ||||||
| Choo et al. (2014) e [ | South of Korea | 26 | Female | 46 | Healthy | 28 | −2 | Included | ||||||
| Choo et al. (2014) f [ | South of Korea | 26 | Female | 46 | Healthy | 28 | −1 | Included | ||||||
| Choo et al. (2014) g [ | South of Korea | 27 | Female | 42 | Healthy | 29 | −1 | Included | ||||||
| Choo et al. (2014) h [ | South of Korea | 27 | Female | 42 | Healthy | 29 | −1 | Included | ||||||
| Choo et al. (2014) i [ | South of Korea | 27 | Female | 42 | Healthy | 29 | −1 | Included | ||||||
| Cotie et al. (2014) [ | Canada | 20 | Female | 30 | Healthy | 32 | −6 | NR | ||||||
| Davison et al. (2008) a [ | Australia | 13 | Both | 45 | Healthy | 34 | 1 | 11 | Both | 44 | Healthy | 35 | 2 | |
| Davison et al. (2008) b [ | Australia | 13 | Both | 46 | Healthy | 33 | 1 | 12 | Both | 45 | Healthy | 33 | −2 | |
| Fayh et al. (2013) [ | Brazil | 17 | Both | 31 | Healthy | 35 | −4 | 18 | Both | 32 | Healthy | 35 | −5 | Not included |
| Franklin et al. (2015) [ | USA | 10 | Female | 30 | Healthy | 34 | −1 | 8 | Female | 31 | Healthy | 32 | 0 | Not included |
| Hamdy et al. (2003) [ | USA | 24 | Both | 49 | Insulin resistance syndrome | 37 | −7 | Not included | ||||||
| Kwon et al. (2011) a [ | South of Korea | 13 | Female | 56 | Type 2 diabetes | 27 | −2 | 15 | Female | 59 | Type 2 Diabetes | 27 | −1 | NR |
| Kwon et al. (2011) b [ | South of Korea | 12 | Female | 56 | Type 2 diabetes | 27 | −1 | 15 | Female | 59 | Type 2 Diabetes | 27 | −1 | NR |
| Olson et al. (2006) [ | USA | 15 | Female | 38 | Healthy | 28 | 2 | 15 | Female | 38 | Healthy | 28 | 0 | Not included |
| Pugh et al. (2014) [ | UK | 13 | Both | 50 | Nonalcoholic fatty liver disease | 30 | −2 | 8 | Both | 47 | Healthy | 30 | −1 | |
| Robinson et al. (2016) [ | USA | 10 | Both | 34 | Healthy | 32 | −3 | 9 | Both | 28 | 33 | 0 | Not included | |
| Swift et al. (2012) a [ | USA | 68 | Female | 57 | Elevated BP | 32 | −1 | 23 | Female | 57 | Elevated BP | 32 | −1 | |
| Swift et al. (2012) b [ | USA | 32 | Female | 56 | Elevated BP | 33 | −1 | 23 | Female | 57 | Elevated BP | 32 | −1 | |
| Swift et al. (2012) c [ | USA | 32 | Female | 56 | Elevated BP | 31 | −1 | 23 | Female | 57 | Elevated BP | 32 | −1 | |
| Vinet et al. (2011) [ | France | 10 | Male | 51 | Healthy | 33 | −2 | Not included | ||||||
| Wycherley et al. (2008) [ | Australia | 13 | Both | 52 | Type 2 diabetes | 34 | −8 | 16 | Both | 53 | Type 2 Diabetes | 35 | −9 | |
Note. NR: no report.
Characteristics of intervention of the included studies.
| Author and year | Exercise intervention | Additional diet intervention | ||||
|---|---|---|---|---|---|---|
| Type | Duration (weeks) | Frequency of sessions (per week) | Duration of session (min) | Intensity | ||
| Ades et al. (2011) a [ | Aerobic | 16 | 1–3 | 40–60 | Low (high-caloric-expenditure) | Yes |
| Ades et al. (2011) b [ | Aerobic | 16 | 1–3 | 25–40 | Higher (lower-caloric-expenditure) | Yes |
| Baynard et al. (2009) a [ | Aerobic | 10 days | 6 | 60 | 70–75% of VO2 peak | No |
| Baynard et al. (2009) b [ | Aerobic | 10 days | 6 | 60 | 70–75% of VO2 peak | No |
| Baynard et al. (2009) c [ | Aerobic | 10 days | 6 | 60 | 70–75% of VO2 peak | No |
| Baynard et al. (2009) d [ | Aerobic | 10 days | 6 | 60 | 70–75% of VO2 peak | No |
| Bhutani et al. (2013) a [ | Aerobic | 12 | 3 | 24–40 | 60–75% of HRmax | Yes |
| Bhutani et al. (2013) b [ | Aerobic | 12 | 3 | 24–40 | 60–75% of HRmax | No |
| Blumenthal et al. (2010) [ | Aerobic | 16 | 3 | 45 | 70–85% of HRR | Yes |
| Choo et al. (2014) a [ | Aerobic | 12 | 3 | 60 | 50–70% of HRR | Yes |
| Choo et al. (2014) b [ | Aerobic | 24 | 3 | 60 | 50–70% of HRR | Yes |
| Choo et al. (2014) c [ | Aerobic | 38 | 3 | 60 | 50–70% of HRR | Yes |
| Choo et al. (2014) d [ | Resistance | 12 | 3 | 60 | 40–60% of MS | Yes |
| Choo et al. (2014) e [ | Resistance | 24 | 3 | 60 | 40–60% of MS | Yes |
| Choo et al. (2014) f [ | Resistance | 38 | 3 | 60 | 40–60% of MS | Yes |
| Choo et al. (2014) g [ | Combined | 12 | 3 | 60 (30 + 30) | 50–70% of HRR | Yes |
| Choo et al. (2014) h [ | Combined | 24 | 3 | 60 (30 + 30) | 50–70% of HRR | Yes |
| Choo et al. (2014) i [ | Combined | 38 | 3 | 60 (30 + 30) | 50–70% of HRR | Yes |
| Cotie et al. (2014) [ | Combined | 16 | 7 | Expend 250 kal/day | 70%/3 set 10 rep | Yes |
| Davison et al. (2008) a [ | Aerobic | 12 | At least 1 | 45 | 75% of HRmax | Yes |
| Davison et al. (2008) b [ | Aerobic | 12 | At least 1 | 45 | 75% of HRmax | Yes |
| Fayh et al. (2013) [ | Aerobic | 10 | 3 | 45 | 70% of HRmax | Yes |
| Franklin et al. (2015) [ | Circuit-based RT | 8 | 2 | 80–90% of 10 RM | No | |
| Hamdy et al. (2003) [ | Aerobic | 24 | 3 | 30 | 60–80% of HRmax | Yes |
| Kwon et al. (2011) a [ | Aerobic | 12 | 5 | 60 | Moderate (3.6–6 METs) | No |
| Kwon et al. (2011) b [ | Resistance | 12 | 5 | 60 | Bands provide 1.2–3.2 kg of resistance | No |
| Olson et al. (2006) [ | Resistance | 1 year | At least 2 | 3 sets 8–10 repetitions | No | |
| Pugh et al. (2014) [ | Aerobic | 12 | 5 | 45 | 60% of HRR | Yes |
| Robinson et al. (2016) [ | Aerobic | 8 | 3 | 30–45 | 75% of HRmax | No |
| Swift et al. (2012) a [ | Aerobic | 24 | 3-4 | Expend 4 kcal/kg | 50% of VO2 peak | No |
| Swift et al. (2012) b [ | Aerobic | 24 | 3-4 | Expend 8 kcal/kg | 50% of VO2 peak | No |
| Swift et al. (2012) c [ | Aerobic | 24 | 3-4 | Expend 12 kcal/kg | 50% of VO2 peak | No |
| Vinet et al. (2011) [ | Aerobic | 8 | 3 | 45 | LIPOXmaxHR ± 5 | No |
| Wycherley et al. (2008) [ | Aerobic | 12 | 4-5 | 50–60 | 60–80% of HRmax | Yes |
Note. HRR: Heart Rate Reserve, MS: Maximum Strength, LIPOXmaxHR: maximum lipid-oxidation point.
FMD protocol and outcomes.
| Author anB3:H25 | Timing of measurement | Placed cuff | Treatment group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Preintervention | Postintervention | Preintervention | Postintervention | |||||||
| mean | SD | mean | SD | mean | SD | mean | SD | |||
| Ades et al. (2011) a [ | Fast | Brachial artery | 2.9 | 3.6 | 6.5 | 3.5 | ||||
| Ades et al. (2011) b [ | Fast | Brachial artery | 3.6 | 4.1 | 4.9 | 3.8 | ||||
| Baynard et al. (2009) a [ | Overnight fast | Brachial artery | 8 | 1.5 | 7.5 | 1.2 | ||||
| Baynard et al. (2009) b [ | 0.5–1 h ingestion | Brachial artery | 6 | 1.1 | 6.3 | 1.1 | ||||
| Baynard et al. (2009) c [ | Overnight fast | Brachial artery | 10.4 | 1.1 | 10.2 | 0.9 | ||||
| Baynard et al. (2009) d [ | 0.5–1 h ingestion | Brachial artery | 9.8 | 0.8 | 8.5 | 0.8 | ||||
| Bhutani et al. (2013) a [ | NR | Brachial artery | 3.8 | 1.2 | 6.4 | 0.8 | 4.8 | 1.2 | 9.7 | 1.8 |
| Bhutani et al. (2013) b [ | NR | Brachial artery | 6.8 | 1.3 | 7.2 | 1.4 | 7 | 3.3 | 6.3 | 3 |
| Blumenthal et al. (2010) [ | Overnight fast | Brachial artery | 4z | 1 | 3.8z | 1 | ||||
| Choo et al. (2014) a [ | Overnight fast | Brachial artery | 11.28 | 3.5 | 11.55 | 3.8 | ||||
| Choo et al. (2014) b [ | Overnight fast | Brachial artery | 11.28 | 3.5 | 11.08 | 4.05 | ||||
| Choo et al. (2014) c [ | Overnight fast | Brachial artery | 11.28 | 3.5 | 10.7 | 3.75 | ||||
| Choo et al. (2014) d [ | Overnight fast | Brachial artery | 10.32 | 3.8 | 11.22 | 4.43 | ||||
| Choo et al. (2014) e [ | Overnight fast | Brachial artery | 10.32 | 3.8 | 10.89 | 4.33 | ||||
| Choo et al. (2014) f [ | Overnight fast | Brachial artery | 10.32 | 3.8 | 11.54 | 4.99 | ||||
| Choo et al. (2014) g [ | Overnight fast | Brachial artery | 11.02 | 3.49 | 11.1 | 3.4 | ||||
| Choo et al. (2014) h [ | Overnight fast | Brachial artery | 11.02 | 3.49 | 12.41 | 4.27 | ||||
| Choo et al. (2014) i [ | Overnight fast | Brachial artery | 11.02 | 3.49 | 11.3 | 4.04 | ||||
| Cotie et al. (2014) [ | NR | Brachial artery | 4 | 0.5 | 6.9 | 0.6 | ||||
| Davison et al. (2008) a [ | NR | Brachial artery | 5.37 | 0.68 | −0.4a | 0.77b | 3.65 | 1.4 | −0.3a | 0.53b |
| Davison et al. (2008) b [ | NR | Brachial artery | 4.05 | 0.51 | 1.5a | 0.68b | 4.12 | 0.75 | 1.8a | 0.89b |
| Fayh et al. (2013) [ | Overnight fast | Brachial artery | 8.1 | 3.6 | 10.7 | 3.6 | 9.9 | 3.4 | 10.1 | 5.8 |
| Franklin et al. (2015) [ | NR | Brachial artery | 9.5 | 1.6 | 9.8 | 1.6 | 8.4 | 3.5 | 8 | 3.3 |
| Hamdy et al. (2003) [ | NR | Brachial artery | 7.9 | 1 | 12.9 | 1.2 | ||||
| Kwon et al. (2011) a [ | 10 h fast | Brachial artery | 4.3 | 1.6 | 6.4 | 1.9 | 4.7 | 1.9 | 4 | 1.9 |
| Kwon et al. (2011) b [ | 10 h fast | Brachial artery | 4.9 | 2.5 | 5.6 | 2.8 | 4.7 | 1.9 | 4 | 1.9 |
| Olson et al. (2006) [ | Overnight fast | Brachial artery | 6.3 | 0.2 | 6.2 | 0.1 | 6.3 | 0.2 | 6 | 0.1 |
| Pugh et al. (2014) [ | NR | Brachial artery | 4.79 | 8.57 | (2.24–4.71)c | 5.94 | 5.32 | (−1.72–1.46)c | ||
| 3.47a | −0.13a | |||||||||
| Robinson et al. (2016) [ | NR | Brachial artery | 8.6 | 4.8 | 7.7 | 2.79 | 9.3 | 4.2 | 9.3 | 4.1 |
| Swift et al. (2012) a [ | Fast | Brachial artery | 4 | 2.6 | 1a | (0.29–1.76)c | 4.7 | 2.4 | −0.5a | (−1.79–0.74)c |
| Swift et al. (2012) b [ | Fast | Brachial artery | 4.4 | 2.4 | 1.5a | (0.48–2.62)c | 4.7 | 2.4 | −0.5a | (−1.79–0.74)c |
| Swift et al. (2012) c [ | Fast | Brachial artery | 3.7 | 2.6 | 1.2a | (0.1–2.24)c | 4.7 | 2.4 | −0.5a | (−1.79–0.74)c |
| Vinet et al. (2011) [ | Overnight fast | Brachial artery | 2.7 | 0.4 | 4.8 | 0.5 | ||||
| Wycherley et al. (2008) [ | Fast | Brachial artery | 4.2 | 1.2 | −0.52a | 1.06b | 2.5 | 0.9 | 0.03a | 0.26b |
Note. aΔmean; bΔSD; c95% confidence interval; zadjusted for value of preintervention; NR: no report.
Methodological scores by Physiotherapy Evidence Database (PEDro) scale.
| Studies | PEDro criterion | Total score | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ||
| Ades et al. (2011) [ | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 9 |
| Baynard et al. (2009) [ | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 6 |
| Bhutani et al. (2013) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Blumenthal et al. (2010) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Choo et al. (2014) [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 9 |
| Cotie et al. (2014) [ | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 |
| Davison et al. (2008) [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 9 |
| Fayh et al. (2013) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Franklin et al. (2015) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Hamdy et al. (2003) [ | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| Kwon et al. (2011) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
| Olson et al. (2006) [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Pugh et al. (2014) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 7 |
| Robinson et al. (2016) [ | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| Swift et al. (2012) [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 8 |
| Vinet et al. (2011) [ | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 5 |
| Wycherley et al. (2008) [ | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 8 |
|
| ||||||||||||
|
| 16 | 12 | 12 | 17 | 3 | 0 | 4 | 9 | 17 | 16 | 17 | |
Note. Each number of PEDro criterion is represented as follows: 1: inclusion and source; 2: random allocation; 3: concealed allocation; 4: baseline comparability; 5: blinded subjects; 6: blinded therapists; 7: blinded assessors; 8: outcomes for >85%; 9: intention-to-treat analysis; 10: between-group comparisons; 11: mean and variability data.
Figure 2Forest plot illustrating effect of exercise intervention on FMD.
Subgroup analysis.
| Moderator variable |
| ES | 95% CI |
| |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Body weight change | |||||
| Increase | 7 | 0.10 | −0.50 | 0.70 | 2.545 |
| 0–2.9 kg loss | 19 | 0.61 | 0.26 | 0.97 | |
| ≥3 kg loss | 8 | 0.70 | 0.12 | 1.28 | |
| Diet intervention | |||||
| Yes | 20 | 0.51 | 0.18 | 0.85 | 0.008 |
| No | 14 | 0.54 | 0.11 | 0.97 | |
| Exercise duration | |||||
| <12 weeks | 8 | 0.09 | −0.50 | 0.68 | 2.868 |
| 12–23 weeks | 15 | 0.61 | 0.20 | 1.02 | |
| ≥24 weeks | 11 | 0.71 | 0.24 | 1.18 | |
| Exercise type | |||||
| Resistance | 6 | 0.43 | −0.22 | 1.07 | 0.601 |
| Aerobic | 24 | 0.52 | 0.18 | 0.85 | |
| Combined | 4 | 0.82 | 0.01 | 1.62 | |
| Exercise intensity | |||||
| Low | 3 | 1.24 | 0.29 | 2.19 | 2.401 |
| Moderate | 30 | 0.47 | 0.19 | 0.75 | |
| High | 1 | 0.27 | −1.38 | 1.93 | |
| Comorbidity | |||||
| No | 21 | 0.26 | −0.06 | 0.58 | 6.392 |
| Yes | 13 | 0.95 | 0.52 | 1.37 | |
| Baseline BMI | |||||
| 25–29.9 | 12 | 0.31 | −0.11 | 0.73 | 1.647 |
| 30–34.9 | 19 | 0.67 | 0.30 | 1.04 | |
| ≥35 | 3 | 0.66 | −0.28 | 1.61 | |
Note. p < 0.05.